Lung Cancer
M25-274; A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Details
ClinicalTrials.gov ID:
NCT06568939
Diagnosis Type:
NA
USOR Number:
- Address
,
P: